These innovative agents represent a significant progression in the treatment of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates exceptional efficacy in lowering blood glucose levels. https://emiliajcme796606.p2blogs.com/37631585/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide